OBJECTIVES: Prognostic models for malignant pleural mesothelioma (MPM) are needed to prevent potentially futile outcomes. We combined MPM plasma biomarkers with validated clinical prognostic indices to determine whether stratification of risk for death in 194 patients with MPM improved. METHODS: Individuals were recruited from three different centers: a discovery cohort (83 patients with MPM) created by combining patients from two U.S. centers and a separate, independent cohort from Canada (111 patients with MPM). Univariable and multivariable analyses were performed on the initial discovery and independent cohorts separately. In the multivariable analyses, prognostic factors were adjusted for the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (PI) of mesothelioma. The prognostic significance of adding plasma biomarker data to the PI was determined by using the likelihood ratio test, comparing models with and without the addition of biomarker to the clinical PI. The predictive ability of the biomarker was then assessed formally using Harrell's C-index by applying the fitted model variables of the discovery cohort to the second, independent cohort, including and not including the biomarker with the PI. RESULTS: Higher levels of osteopontin and mesothelin were individually associated with worse prognosis after adjusting for the PI. In the independent cohort, incorporating either plasma osteopontin or mesothelin into the baseline predictive PI model substantively and statistically significantly improved Harrell's C-statistic. In the final prognostic model, log-osteopontin, EORTC clinical prognostic index, and hemoglobin remained as independently significant predictors and the entire prognostic model improved the optimism-corrected Harrell's C-index significantly, from 0.718 (0.67-0.77) to 0.801 (0.77-0.84). CONCLUSIONS: These data suggest a possible role for preoperative plasma biomarkers to improve the prognostic capability of the EORTC PI of MPM.
OBJECTIVES: Prognostic models for malignant pleural mesothelioma (MPM) are needed to prevent potentially futile outcomes. We combined MPM plasma biomarkers with validated clinical prognostic indices to determine whether stratification of risk for death in 194 patients with MPM improved. METHODS: Individuals were recruited from three different centers: a discovery cohort (83 patients with MPM) created by combining patients from two U.S. centers and a separate, independent cohort from Canada (111 patients with MPM). Univariable and multivariable analyses were performed on the initial discovery and independent cohorts separately. In the multivariable analyses, prognostic factors were adjusted for the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (PI) of mesothelioma. The prognostic significance of adding plasma biomarker data to the PI was determined by using the likelihood ratio test, comparing models with and without the addition of biomarker to the clinical PI. The predictive ability of the biomarker was then assessed formally using Harrell's C-index by applying the fitted model variables of the discovery cohort to the second, independent cohort, including and not including the biomarker with the PI. RESULTS: Higher levels of osteopontin and mesothelin were individually associated with worse prognosis after adjusting for the PI. In the independent cohort, incorporating either plasma osteopontin or mesothelin into the baseline predictive PI model substantively and statistically significantly improved Harrell's C-statistic. In the final prognostic model, log-osteopontin, EORTC clinical prognostic index, and hemoglobin remained as independently significant predictors and the entire prognostic model improved the optimism-corrected Harrell's C-index significantly, from 0.718 (0.67-0.77) to 0.801 (0.77-0.84). CONCLUSIONS: These data suggest a possible role for preoperative plasma biomarkers to improve the prognostic capability of the EORTC PI of MPM.
Authors: Kevin Hollevoet; Kristiaan Nackaerts; Robert Gosselin; Walter De Wever; Lionel Bosquée; Paul De Vuyst; Paul Germonpré; Eliane Kellen; Catherine Legrand; Yoshiro Kishi; Joris R Delanghe; Jan P van Meerbeeck Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Vivien H C Bramwell; Gordon S Doig; Alan B Tuck; Sylvia M Wilson; Katia S Tonkin; Anna Tomiak; Francisco Perera; Theodore A Vandenberg; Ann F Chambers Journal: Clin Cancer Res Date: 2006-06-01 Impact factor: 12.531
Authors: Joachim Schneider; Hans Hoffmann; Hendrik Dienemann; Felix J F Herth; Michael Meister; Thomas Muley Journal: J Thorac Oncol Date: 2008-11 Impact factor: 15.609
Authors: J W Thoms; A Dal Pra; P H Anborgh; E Christensen; N Fleshner; C Menard; K Chadwick; M Milosevic; C Catton; M Pintilie; A F Chambers; R G Bristow Journal: Br J Cancer Date: 2012-08-07 Impact factor: 7.640
Authors: B Ghanim; T Klikovits; M A Hoda; G Lang; I Szirtes; U Setinek; A Rozsas; F Renyi-Vamos; V Laszlo; M Grusch; M Filipits; A Scheed; M Jakopovic; M Samarzija; L Brcic; D Stancic-Rokotov; I Kern; A Rozman; G Dekan; W Klepetko; W Berger; T Glasz; B Dome; B Hegedus Journal: Br J Cancer Date: 2015-01-29 Impact factor: 7.640
Authors: Michaela B Kirschner; Emily Pulford; Mir Alireza Hoda; Anita Rozsas; Kim Griggs; Yuen Yee Cheng; J James B Edelman; Steven C Kao; Rebecca Hyland; Yawen Dong; Viktoria László; Thomas Klikovits; Michael P Vallely; Michael Grusch; Balazs Hegedus; Balazs Dome; Walter Klepetko; Nico van Zandwijk; Sonja Klebe; Glen Reid Journal: Br J Cancer Date: 2015-08-11 Impact factor: 7.640
Authors: Harvey I Pass; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck; Valerie W Rusch Journal: J Thorac Oncol Date: 2014-06 Impact factor: 15.609
Authors: David T Arnold; Duneesha De Fonseka; Fergus W Hamilton; Najib M Rahman; Nick A Maskell Journal: Br J Cancer Date: 2017-02-07 Impact factor: 7.640